经动脉药盒灌注治疗中晚期胰腺癌  

The treatment of advanced pancrentic cancer by arterial infusion chemotherapy via port catheter system

作　　者：尹国文[1] 陈世唏[1] 席玮[1] 

机构地区：[1]江苏省肿瘤医院介入科,210009

出　　处：《江苏医药》2005年第10期750-751,共2页Jiangsu Medical Journal

摘　　要：目的评价经动脉药盒灌注盐酸吉西他滨、5-氟脲嘧啶(5-FU)和白细胞介素-2(IL-2)对不同部位中晚期胰腺癌的治疗价值。方法回顾性分析63例不能手术切除的中晚期胰腺癌患者,经皮下动脉药盒系统灌注上述药治疗后不同部位胰腺癌的临床受益反应率(CBRR)和生存期。结果63例患者CBRR为44.4%,频数分布法计算中位生存期5.9个月,中位疾病进展期2.8个月。Kaplan-meier法计算6个月和9个月累积生存率分别为49.3%和26.8%。46例胰头癌患者和17例胰体尾癌患者6个月累积生存率分别为63.5%和40.6%,9个月分别为40.7%和12.3%。胰头癌患者和胰体尾癌患者CBRR分别为54.3%和17.6%(P<0.01),中位生存期分别为9.1个月和4.3个月。中位疾病进展期分别为3.5个月和2.1个月。结论经皮下动脉药盒系统灌注上述药对中晚期胰腺癌患者有较高的CBRR,可延长其生存期;胰头癌的疗效优于胰体尾部。Objective To evaluate the efficacy of arterial continuous infusing gemcitabine, 5-FU,IL-2 via port catheter system （PCS） in the tseatment of advanced pancreatic cancer. Methods To retrospectively analyze the clinical effectiveness of transarteriaI infusion chemotherapy of gemcitabine,5 FU and IL-2 via PCS in the treatment of 63 patients with advanced pancreatic cancer. Results The clinical benefit response rate （CBRR） in 63 cases was 44.6%. Medial survival time for all patients was 5.9 months,Median time to tumor progression was 2.8 months. The CBRR in 46 cases with head-pancreatic cancer was 54.3%, which was obviously highdr than 17.6% in 17 cases with body and end pancreatic cancer （P〈0. 01）. Conclusion py of gemcitabine, 5-FU and IL-2 via PCS can provide higher CBRR,especiallv in those head pancreatic cancer. The continuous arterial infusion chemotherapatients of advanced pancrentic cancer with higher CBRR,especially in those head pancreatic cancer.

关 键 词：动脉灌注 胰腺癌 介入 药盒 中晚期胰腺癌 动脉药盒系统 灌注治疗 KAPLAN-MEIER法 胰腺癌患者 中位生存期 

分 类 号：R735.9[医药卫生—肿瘤] R734.2[医药卫生—临床医学]